secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001493152-23-016922
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma Q1 net loss $5.2M; progresses COVID-19/flu trials; raises $4M
------------------------------------------------------------------------------

- Net loss of $5.2M ($0.64/share) vs $4.2M ($0.52) in Q1 2022; R&D expense $3.9M (up from $2.9M).
- Cash of $34.0M at March 31, 2023; working capital $33.8M; 8.1M shares outstanding.
- Raised $4M via private placement from directors Dr. Phillip Frost and Fred Hassan; Hassan joined board.
- Submitted application for Phase 1 trial of COVID-19 oral protease inhibitor CDI-988 in Australia.
- Expects to start Phase 2a human challenge study for influenza A candidate CC-42344 in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223016922/0001493152-23-016922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223016922/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer